Home / Science / New Cancer Therapy Targets Tumors With Dual Attack
New Cancer Therapy Targets Tumors With Dual Attack
10 Sep
Summary
- Researchers developed immune cells targeting cancer via two distinct biological routes.
- Experimental cells show stronger killing and resilience against cancer evasion.
- This approach could significantly reduce manufacturing costs for cell therapies.
Researchers have engineered a novel type of immune cell, dubbed AlloESO-T cells, designed to combat solid tumors more effectively. These cells employ a dual-targeting strategy, attacking cancer through two distinct biological pathways to overcome common evasion tactics.
The experimental therapy utilizes an engineered T-cell receptor to recognize the NY-ESO-1 protein and natural killer receptors to detect stressed malignant cells independently. This dual mechanism aims to maintain effectiveness even if cancer cells lose the primary targeted antigen.
In preclinical models, AlloESO-T cells exhibited superior cancer-cell killing, selective tumor homing, and sustained activity. Furthermore, the manufacturing process from cord blood stem cells is projected to be significantly more cost-effective than current personalized cell therapies, with an estimated cost of $5,000 per dose.
While promising, extensive safety studies and clinical-grade manufacturing protocols are still required before human trials can commence. Researchers will carefully assess potential off-tumor effects, dose, biodistribution, and persistence.
